ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

View source version on?businesswire.com:?https://www.businesswire.com/news/home/20201019005214/en/
INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O?Konek 781-895-0600 courtney.okonek@immunogen.com OR FTI Consulting Robert Stanislaro 212-850-5657 robert.stanislaro@fticonsulting.com Huadong Medicine Bo Chen +86 571 8990 3290 pretor@eastchinapharm.com Source:?ImmunoGen, Inc.